Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313366294> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4313366294 endingPage "71.5" @default.
- W4313366294 startingPage "71.5" @default.
- W4313366294 abstract "Abstract The Inducible T cell Costimulator (ICOS, CD278) is a receptor in the CD28 family of B7-binding proteins expressed mostly by activated T cells. Upon binding to its ligand ICOS-L expressed on APCs,T cells are further activated by ICOS, resulting in their expansion and production of effector cytokines. Clinical data in patients treated with anti-CTLA-4 or anti-PD-1 mAbs have shown that ICOShiT cells correlated with an increased treatment response in these patients. Here, we report the design of a high avidity pentavalent form of the human ICOS-L extracellular domain fused to a short α-helical peptide from the human cartilage oligomeric matrix protein (COMP). This ICOS agonist, termed ICOS-L.COMP, spontaneously assembles into stable pentamers, binds tightly to both human and murine ICOS (SPR; Kd<10 nM) and co-stimulates (with anti CD3 mAb) the proliferation and cytokine release of both murine and human CD4+ and CD8+ T cells when added as a soluble factor (unlike ICOS-L.Fc). Soluble ICOS-L.COMP also phosphorylates Akt in activated T cells and enhances anti-tumor immune responses in tumor-bearing mice [murine MC38 or CT26 tumors] treated with either anti-murine PD-1 or anti-murine CTLA-4 mAb. Impressively, most mice treated with ICOS-L.COMP combined with an immune checkpoint inhibitor were either cured or displayed a stable tumor burden in contrast to checkpoint monotherapies (delayed tumor progression) or when ICOS-L.COMP was given as a monotherapy (comparable to no treatment). Importantly, ICOS-L.COMP lacks a Fc domain thus eliminating Fc-associated off-target adverse effects. In summary, our results suggest that ICOS-L.COMP represents a new and powerful biologic to be used in combination with existing immune checkpoint inhibitors." @default.
- W4313366294 created "2023-01-06" @default.
- W4313366294 creator A5006919436 @default.
- W4313366294 creator A5023516628 @default.
- W4313366294 creator A5030651983 @default.
- W4313366294 creator A5053344913 @default.
- W4313366294 creator A5083823187 @default.
- W4313366294 date "2019-05-01" @default.
- W4313366294 modified "2023-10-09" @default.
- W4313366294 title "A powerful ICOS agonist that enhances anti-tumor immune responses restored by immune checkpoint inhibitors" @default.
- W4313366294 doi "https://doi.org/10.4049/jimmunol.202.supp.71.5" @default.
- W4313366294 hasPublicationYear "2019" @default.
- W4313366294 type Work @default.
- W4313366294 citedByCount "1" @default.
- W4313366294 crossrefType "journal-article" @default.
- W4313366294 hasAuthorship W4313366294A5006919436 @default.
- W4313366294 hasAuthorship W4313366294A5023516628 @default.
- W4313366294 hasAuthorship W4313366294A5030651983 @default.
- W4313366294 hasAuthorship W4313366294A5053344913 @default.
- W4313366294 hasAuthorship W4313366294A5083823187 @default.
- W4313366294 hasConcept C148125776 @default.
- W4313366294 hasConcept C153911025 @default.
- W4313366294 hasConcept C154317977 @default.
- W4313366294 hasConcept C159654299 @default.
- W4313366294 hasConcept C167672396 @default.
- W4313366294 hasConcept C179223381 @default.
- W4313366294 hasConcept C185592680 @default.
- W4313366294 hasConcept C202751555 @default.
- W4313366294 hasConcept C203014093 @default.
- W4313366294 hasConcept C2776090121 @default.
- W4313366294 hasConcept C502942594 @default.
- W4313366294 hasConcept C55493867 @default.
- W4313366294 hasConcept C86803240 @default.
- W4313366294 hasConcept C8891405 @default.
- W4313366294 hasConcept C95444343 @default.
- W4313366294 hasConceptScore W4313366294C148125776 @default.
- W4313366294 hasConceptScore W4313366294C153911025 @default.
- W4313366294 hasConceptScore W4313366294C154317977 @default.
- W4313366294 hasConceptScore W4313366294C159654299 @default.
- W4313366294 hasConceptScore W4313366294C167672396 @default.
- W4313366294 hasConceptScore W4313366294C179223381 @default.
- W4313366294 hasConceptScore W4313366294C185592680 @default.
- W4313366294 hasConceptScore W4313366294C202751555 @default.
- W4313366294 hasConceptScore W4313366294C203014093 @default.
- W4313366294 hasConceptScore W4313366294C2776090121 @default.
- W4313366294 hasConceptScore W4313366294C502942594 @default.
- W4313366294 hasConceptScore W4313366294C55493867 @default.
- W4313366294 hasConceptScore W4313366294C86803240 @default.
- W4313366294 hasConceptScore W4313366294C8891405 @default.
- W4313366294 hasConceptScore W4313366294C95444343 @default.
- W4313366294 hasIssue "1_Supplement" @default.
- W4313366294 hasLocation W43133662941 @default.
- W4313366294 hasOpenAccess W4313366294 @default.
- W4313366294 hasPrimaryLocation W43133662941 @default.
- W4313366294 hasRelatedWork W1513178816 @default.
- W4313366294 hasRelatedWork W1558649589 @default.
- W4313366294 hasRelatedWork W1964440670 @default.
- W4313366294 hasRelatedWork W1969897672 @default.
- W4313366294 hasRelatedWork W2040866987 @default.
- W4313366294 hasRelatedWork W2060451389 @default.
- W4313366294 hasRelatedWork W2062443745 @default.
- W4313366294 hasRelatedWork W2112859782 @default.
- W4313366294 hasRelatedWork W2370976773 @default.
- W4313366294 hasRelatedWork W2371815043 @default.
- W4313366294 hasVolume "202" @default.
- W4313366294 isParatext "false" @default.
- W4313366294 isRetracted "false" @default.
- W4313366294 workType "article" @default.